
    
      All subjects will receive 28 days of ITX 5061 beginning at the time of transplant.

      Dosing of ITX 5061 is as follows:

      Day of Transplant prior to surgery: ITX 5061 300 mg Day of Transplant following surgery: ITX
      5061 300 mg Post-Operative Days 1-6: ITX 5061 300 mg Post-Operative Days 7-27: ITX 5061 150
      mg

      Subjects will be monitored for HCV RNA levels, HDL cholesterol and ITX 5061 drug
      concentration levels.

      A liver biopsy will be performed at 6 months post-transplant to assess for histological signs
      of HCV recurrence.
    
  